Sign In
Buy SRDX
$42.98
+0 (+0%)
At Close: Feb 24, 2026
SurModics (SRDX) Reports Q2 Earnings: What Key Metrics Have to Say
11:00am, Wednesday, 30'th Apr 2025
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estima
SurModics (SRDX) Reports Q2 Loss, Misses Revenue Estimates
09:20am, Wednesday, 30'th Apr 2025
SurModics (SRDX) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.07 per share a year ago.
Surmodics Reports Second Quarter of Fiscal Year 2025 Financial Results; Introduces Fiscal Year 2025 Financial Guidance
07:00am, Wednesday, 30'th Apr 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial res
Surmodics to Report Second Quarter of Fiscal 2025 Financial Results on April 30
06:00pm, Monday, 28'th Apr 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that second
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon
07:00am, Tuesday, 22'nd Apr 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the publica
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System
01:40pm, Friday, 04'th Apr 2025
Surmodics launches the Pounce XL Thrombectomy System, aiming to enhance clot removal efficiency, improve patient outcomes, and expand its portfolio of vascular interventions.
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the commerc
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now
07:50am, Tuesday, 18'th Mar 2025
SRDX stock falls more than 26% so far this year. However, this provides a unique opportunity to generate double-digit returns within a couple of months.
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
04:00pm, Friday, 07'th Mar 2025
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR
09:00pm, Thursday, 06'th Mar 2025
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, today provided the following stateme
FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics
04:22pm, Thursday, 06'th Mar 2025
The U.S. Federal Trade Commission sued on Thursday to block medical device coatings maker Surmodics' acquisition by private equity firm GTCR, with the regulatory agency alleging the deal was anticompe
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:35am, Monday, 03'rd Feb 2025
The heavy selling pressure might have exhausted for SurModics (SRDX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced the success
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up
12:20pm, Friday, 31'st Jan 2025
Despite the strength in Pounce thrombectomy device platforms, SRDX's first-quarter fiscal 2025 top line is dampened by weak segmental revenues.
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics
10:35am, Thursday, 30'th Jan 2025
The headline numbers for SurModics (SRDX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street est
